8-K: Revelation Biosciences Faces Nasdaq Delisting Threat Due to Stockholders' Equity Deficiency

Revelation Biosciences has received a notification from Nasdaq for failing to meet the minimum stockholders' equity requirement for continued listing.

Summary

• Revelation Biosciences received a letter from Nasdaq on August 14, 2024, stating the company is not in compliance with the minimum stockholders' equity requirement of $2,500,000 for continued listing.
• The company's stockholders' equity was reported as $1,140,421 in their June 30, 2024, quarterly report, falling short of the required amount.
• Revelation Biosciences also does not meet the alternative listing standards of a market value of listed securities of at least $35 million or net income of $500,000 from continuing operations.
• The company has 45 days to submit a plan to regain compliance, and if accepted, Nasdaq may grant an extension of up to 180 days to evidence compliance.
• If the plan is not accepted or the company fails to regain compliance within the extension period, they have the right to a hearing before an independent panel.
• The company intends to take all reasonable measures to regain compliance and remain listed on Nasdaq, but there is no guarantee of success.
• The noncompliance does not immediately affect the trading of the company's common stock or warrants, which will continue to trade on Nasdaq under the symbols REVB and REVBW, respectively.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event with the company facing potential delisting, which is a major concern for investors. The company is taking steps to address the issue, but the outcome is uncertain.

Positives

• The company has 45 days to submit a plan to regain compliance.
• Nasdaq may grant an extension of up to 180 days if the plan is accepted.
• The company has the right to a hearing if the plan is not accepted or if they fail to regain compliance within the extension period.
• The company's stock and warrants will continue to trade on Nasdaq during this period.

Negatives

• Revelation Biosciences is not in compliance with Nasdaq's minimum stockholders' equity requirement.
• The company's stockholders' equity is significantly below the required $2,500,000, at $1,140,421.
• The company also fails to meet alternative listing standards related to market value and net income.
• There is no guarantee that Nasdaq will accept the company's plan or that the company will regain compliance.

Risks

• There is a risk that Nasdaq may not accept the company's plan to regain compliance.
• The company may fail to regain compliance within the given extension period.
• If the company fails to regain compliance, it could face delisting from Nasdaq.
• Delisting could negatively impact the company's stock price and investor confidence.

Future Outlook

The company intends to submit a plan to regain compliance with Nasdaq listing rules and take all reasonable measures to remain listed, but there is no assurance of success.

Management Comments

• The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and remain listed on Nasdaq.

Industry Context

This announcement highlights the challenges faced by smaller biotech companies in maintaining listing compliance, particularly those with limited revenue and ongoing research and development expenses. It is not uncommon for companies in this sector to face such challenges.

Comparison to Industry Standards

• Many small-cap biotech companies struggle to maintain the minimum stockholders' equity required by exchanges like Nasdaq.
• Companies like Agenus Inc. and Celldex Therapeutics have faced similar challenges in the past, highlighting the volatility and risk associated with the sector.
• The requirement of $2.5 million in stockholders' equity is a standard benchmark for Nasdaq Capital Market listings, and failure to meet this is a common reason for delisting notices.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty about the company's future.
• The company's reputation may be negatively impacted.

Next Steps

• The company will submit a plan to Nasdaq within 45 days to regain compliance.
• Nasdaq will review the plan and may grant an extension of up to 180 days.
• The company may have a hearing before an independent panel if the plan is not accepted or if they fail to regain compliance within the extension period.

Key Dates

Keywords

Nasdaq, delisting, stockholders' equity, compliance, listing rules, REVB, REVBW